A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
Case Western Reserve University recently scored a $1.125 million grant from the National Science Foundation to help fuel its work, with a focus on MRI.
Researchers examined data from more than 21,000 patients treated from 1997 to 2018, publishing their findings in the Journal of the American Heart Association.
